OXFORD, UK – 19 October 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ImplaVax® enabled pandemic flu vaccine.
Provides roadmap to commercial agreement based on shared objective to secure patient access to innovative and cost-effective cancer medicines
Agreement with one of the largest public healthcare systems globally demonstrates EQRx’s commitment to offering new medicines to patients at radically lower prices
EQRx’s lead cancer programs, aumolertinib and sugemalimab, have received Innovation Passport designations through the Innovative Licensing and Access Pathway (ILAP)
Oxford, UK, 19 October 2021 – Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, has expanded its R&D capabilities by taking new laboratory and office space in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies.
Leading biotech product development consultancy Boyds has added two experienced product development experts to its team, amid growing demand for specialist Product Development services from clients in the UK, Europe and the US.
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announced plans today to offer contract development and manufacturing services. CTI will launch the new initiative, focusing on offerings that will enhance cell and gene therapy capabilities.
Edinburgh and Cambridge, UK, 1 October 2021 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made five new appointments to its scientific team, to support and accelerate its R&D.
Oxford, UK, October 5 2021 – Magdalen College Oxford, owner of The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies, and an affiliate of GIC have entered into a Strategic Partnership to accelerate the development of The Oxford Science Park.
The UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) and the National Cancer Research Institute (NCRI), are running a survey for researchers, veterinarians and animal technicians who use rodents in cancer research. The survey aims to identify current and emerging practices and trends in the field, which will help in the revision of the ‘Guidelines for the welfare and use of animals in cancer research' (Workman et al. 2010).